Efficacy and plasma concentration analysis of Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infection

Abstract

Abstract: AIM: To investigate the relationship of clinical efficacy, blood trough concentration and adverse reavtion, which in the treatment of methicillin-resistant Staphylococcus aureus infection with Vancomycin. METHODS: The clinical data of 82 hospital patients who were infected by methicillin-resistant Staphylococcus aureus and treated with Vancomycin from January 2008 to October 2009 were retrospectively analyzed the clinic efficacy, bacteriological treatment, adverse reaction were observed, and the blook trough concentration was detected. RESULTS: The treatment effective rate of Vancomycin-blood trough concentration which was less than 5 μg/mL, in the range of 5-10 μg/mL, and greater than 10 μg/mL were 68.75%, 72.73% and 81.82%. The bacterial clearance rates were 62.50%, 68.18% and 72.73%. One case of blood trough concentration of 14.6 μg/mL in patients with renal toxicity. CONCLUSION: Increasing the blood trough concentration of Vancomycin can improve the treatment of methicillin-resistant Staphylococcus aureus infection in the efficacy and bacterial eradication rates, but the probability of renal toxicity adverse reactions will also increase accordingly.

Key words: Vancomycin, Methicillin-resistant Staphylococcus aureus, Blood trough concentration

CLC Number:

HUA Jun-yan, TIAN Wei-qiang, ZHU Ya-yan, YU Hui-kang. Efficacy and plasma concentration analysis of Vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infection[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(6): 673-677.

References

[1] Tanaka M,Drii T,kobayashi H,et al. Examination of factors affecting efficacy and adverse effect,for the retrospective study of vancomycin hydrochloride(VCM)[J].药学杂志,2001,121(8): 621-629.
[2] 杨利荣,刘兰.万古霉素在危重病感染中的应用[J].中国误诊学杂志,2005,5(14): 2702-2703.
[3] 郑治渊,郑安琳,朱华,等.高龄老人严重感染应用万古霉素治疗的安全性研究[J].老年医学与保健,2004,10(4): 237-239.
[4] 马越,陈鸿波,姚蕾,等.耐甲氧西林金黄色葡萄球菌对万古霉素敏感性的变迁[J].中华内科杂志,2002,41(1):31-36.
[5] Moise PA,Schentag JJ.Vancomycint reatment failures in Staphylococcus aureus lower respiratory tract infections [J].Int J Antimicrob Agents,2000,16(Suppl 1):S31-S34.
[6] King DW,Smith MA. Proliferativere sponses observed following vancomycin treatment in renal proxima tubule epithelial cells [J].Toxicol In Vitro,2004,18(6):797-803.
[7] Celik I,Cihangiroglu M,Ilhan M,et al.Protective effects of different antioxidants and amrinone on vancomy cininduced nephrotoxicity[J].Basic Clin Pharmacol Toxicol,2005,97(5):325-332.
[8] Nishino Y, Takemura S, Minamiyama Y, et al. Inhibition of vancomycin-induced nephrotoxicity by targeting superoxide dismutase to renal proximal tubule cells intherat[J].Redox Rep,2002,7(5):317-319.
[9] 王超,王婧.耐甲氧西林金黄色葡萄球菌的临床治疗[J].中国医刊,2007,42(3): 18-19.
[10] Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses(at least four grams per day)are as sociated with an increased incidence of nephrotoxicity[J]. Antimicrob Agents Chemother, 2008,52(4):1330-1336.
[11] Rybak MJ, Abate BJ, Kang SL, et al. Prospectiv eevaluation of the effect of an aminogly coside dosing regimen on rates of observed nephrotoxicity and ototoxicity[J].Antimicrob Agents Chemother, 1999,43(7):1549-1555.
[12] Malacarne P, Bergamasco S, Donadio C. Nephrotoxicity due to combination antibiotic therapy with vancomycin and aminoglycosides in septic critically ill patients[J]. Chemotherapy, 2006, 52 (4): 178-184.
[13] Cunha BA,Mohan SS,Hamid N,et al.Cost-ineffectiveness of serum vancomycin levels[J].Eur J Clin Microbiol Infect Dis,2007,26(7):509-511.
[14] Hidayat LK,Hsu DI,Quist R,et al.High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections:efficacy and toxicity [J].Arch Intern Med, 2006, 166 (19): 2138-2144.
[15] 梁蓓蓓,王睿. 利奈唑胺、去甲万古霉素等抗菌药物对耐甲氧西林金黄色葡萄球菌的抗菌活性[J]. 中国临床药理学与治疗学,2008,13(9):1044-1047.
[16] 肖秀美,刘振英,张晓伟,等. 利奈唑胺对临床分离阳性球菌的体外敏感性分析[J]. 中国临床药理学与治疗学,2008,13(9):1048-1052.